Short-term outcomes after prostate cancer diagnosis and treatment in France

An article available in full on the Medscape web site provides an overview of short-term outcomes of > 43,000 men diagnosed with prostate cancer in France in 2009 and followed for 2 years based on data in the French national health insurance information system (SNIIRAM). You do need to register with Medscape to be able to read the article (but registration is free). … READ MORE …

Over-use of PSA testing in men > 65 with short life expectancies?

Why is it that we seem to be so focused on testing for risk of prostate cancer in older men with life expectancies of < 10 years, i.e., men who are almost certainly at very low risk for clinically significant disease? … READ MORE …

Prostate cancer mortality rates in the UK drop by 21 percent

According to a report in the Daily Telegraph, Cancer Research UK is claiming that deaths from prostate cancer in the UK have drop by 20.8 percent during the 19-year period from 1991-93 to 2010-12. … READ MORE …

Early identification of androgen receptor gene amplification and prostate cancer risk

Historically, it has generally been assumed that androgen receptor gene amplification was a result of androgen deprivation therapy (ADT) and occurred in some 20 to 30 percent of men with castration-resistant prostate cancer (CRPC). However, … READ MORE …

ERSPC mortality data at 13 years of follow-up published

The Lancet has just published previously reported data from the European Randomized Study of Screening for Prostate Cancer (the ERSPC trial) at 13 years of follow-up. These data were first reported earlier this year at the annual meeting of the EAU, and we commented then on the significance of these data. … READ MORE …

Vasectomy and prostate cancer — the debate evolves

As regular readers will be well aware, the question of whether there is a real cause and effect association between having a vasectomy and the later risk for diagnosis of prostate cancer is controversial and unanswered in any absolute sense. However, there are new data that we can now put on the table … … READ MORE …

Maybe this time … a real answer to the value of PSA screening?

We have frequently referred to an ongoing trial in the UK known as the ProtecT trial. That trial is comparing the effectiveness and safety of surgery, radiation therapy, active surveillance as treatments for well-characterized men diagnosed with localized prostate cancer … but there is something else important we hadn’t realized … … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,134 other followers